Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
894 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07372508 | Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study(GALACTIC-1) | recruiting | N/A | 500 | NHS Greater Glasgow and ClydeOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 |
| NCT05573126 | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | recruiting | Phase 1 / Phase 2 | 95 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT05700149 | Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | recruiting | — | 300 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 15 | Jun 22, 2026 | clinicaltrials |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | recruiting | Phase 1 | 396 | ExelixisINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL(SOUNDTRACK-D2) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 11 | Jun 18, 2026 | clinicaltrials |
| NCT05093231 | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Cambridge University Hospitals NHS Foundation TrustOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT05463263 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 180 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | recruiting | Phase 1 | 70 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT06964438 | Postoperative Electrical Muscle Stimulation Two(POEMS2) | recruiting | N/A | 45 | University of NottinghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | recruiting | Phase 3 | 50 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06414057 | HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks | recruiting | — | 500 | University of EdinburghOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05430971 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | recruiting | — | 200 | Immune Oncology Research InstituteOTHER | 15 | Jun 5, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT06987045 | Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study(TransPRIDE) | recruiting | — | 500 | Queen Mary University of LondonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07622953 | Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological Cancers(VIOLET) | recruiting | — | 250 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | recruiting | Phase 1 | 100 | Apollo Therapeutics LtdINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT07391280 | Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department(SEARCH-ED) | recruiting | N/A | 17,000 | NHS Greater Glasgow and ClydeOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT02443831 | CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia | recruiting | Phase 1 | 50 | University College, LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03151629 | International Registry for Men With Advanced Prostate Cancer (IRONMAN)(IRONMAN) | recruiting | — | 5,000 | Prostate Cancer Clinical Trials ConsortiumOTHER | 15 | May 22, 2026 | clinicaltrials |
| NCT06551142 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)(PanTumor-101) | recruiting | Phase 1 | 845 | GlaxoSmithKlineINDUSTRY | 13 | May 22, 2026 | clinicaltrials |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer(AZUR-4) | recruiting | Phase 2 | 120 | GlaxoSmithKlineINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | recruiting | Phase 1 / Phase 2 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer(DIAMOND) | recruiting | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07189403 | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT00461188 | Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA | recruiting | — | 10,000 | Barts & The London NHS TrustOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06504147 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | recruiting | Phase 2 | 114 | Oncoinvent Solutions ASINDUSTRY | 6 | May 20, 2026 | clinicaltrials |
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients(SAFIR-ABC10) | recruiting | Phase 3 | 800 | UNICANCEROTHER | 3 | May 19, 2026 | clinicaltrials |
| NCT05685173 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas(ATHENA-1) | recruiting | Phase 1 | 107 | Regeneron PharmaceuticalsINDUSTRY | 5 | May 19, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT07597798 | EVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy(EVERiST) | recruiting | — | 40 | University College, LondonOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05727020 | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma(VAPOR) | recruiting | — | 1,005 | Imperial College LondonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07541911 | A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy(LaserSAFE) | recruiting | N/A | 693 | University College, LondonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials